NCT00670358View on ClinicalTrials.gov

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

August 25, 2008

Primary Completion Date

May 7, 2021

Study Completion Date

October 4, 2024

Conditions
Lymphoma
Interventions
BIOLOGICAL

pegfilgrastim

BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

lenalidomide

DRUG

prednisone

DRUG

vincristine sulfate

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

Trial Locations (3)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic, Rochester

85259-5499

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER